Sun European Partners, LLP (“Sun European Partners” or “Sun”) today announces that one of its affiliates has completed the sale of its investment in NextPharma (or “the company”), a leading pharmaceutical contract development and manufacturing organisation, to Funds advised by CapVest Partners LLP.
NextPharma was acquired by an affiliate of Sun European Partners in 2011. Over the last six years, Sun has more than doubled NextPharma’s profitability by optimising the manufacturing footprint, improving the company’s efficiencies and increasing top line growth above market levels.
Lionel de Posson, Principal at Sun European Partners, said: “Once again, the strategy employed by Sun European Partners has allowed for a successful exit and we are delighted with the progress made by the company during our ownership.”
